BAHORUCO, Dominican Republic – The men in ragged clothes, many barefoot and covered in grime, scramble deep into the earth, searching for veins of a blue-green stone believed to exist only in the ...
Larimar Therapeutics held its breath for over a year, but the FDA has finally given the biotech a green light to continue trials of its lead, and only, asset this year. To coincide with its ...
Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025, focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results